Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 338 free, full-text research articles on human participants. First 3 results:

Glypican-1-antibody-conjugated Gd-Au nanoclusters for FI/MRI dual-modal targeted detection of pancreatic cancer.
 

Author(s): Xin Huang, Chengqi Fan, Huanhuan Zhu, Wenjun Le, Shaobin Cui, Xin Chen, Wei Li, Fulei Zhang, Yong Huang, Donglu Sh, Zheng Cui, Chengwei Shao, Bingdi Chen

Journal:

 

Pancreatic cancer (PC) has a poor prognosis with high mortality, due to the lack of effective early diagnostic and prognostic tools.

Last Updated: 31 Dec 1969

Go To URL
Krüppel-Like Factor 4 Inhibits Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis by Down-Regulating Caveolin-1 Expression.
 

Author(s): Zhonglin Zhu, Zhilong Yu, Jianfeng Wang, Lisheng Zhou, Jing Zhang, Bin Yao, Jin Dou, Zhengjun Qiu, Chen Huang

Journal: Cell. Physiol. Biochem.. 2018 ;46(1):238-252.

 

Krüppel-like factor 4 (KLF4), a member of the KLF family of zinc finger transcription factors, has been identified as a tumor suppressor gene in a variety of tumors. However, the molecular mechanisms by which KLF4 inhibits epithelial-to-mesenchymal transition (EMT) and metastasis ...

Last Updated: 31 Dec 1969

Go To URL
Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy.
 

Author(s): Yu Zhang, Xiaofei Zhu, Denghui Liu, Jiaqi Song, Huojun Zhang, Jianping Lu

Journal:

 

To identify the value of the pre-treatment apparent diffusion coefficient (ADC) derived from diffusion weighted imaging (DWI) in predicting the overall survival (OS) for locally advanced pancreatic cancer (LAPC) treated with Cyberknife followed by sequential S-1 chemotherapy.

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 9 free, full-text review articles on human participants. First 3 results:

Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
 

Author(s): Ying Yang, Shirong Yan, Hui Tian, Yixi Bao

Journal: Medicine (Baltimore). 2018 Mar;97(9):e9994.

 

Because of the high malignant degree of pancreatic cancer (PC), the early diagnosis of PC is of great concern. Macrophage inhibitory cytokine-1 (MIC-1) was reported to be a potential diagnostic biomarker, but its diagnostic value is indeterminate. Therefore, we performed this meta-analysis ...

Last Updated: 31 Dec 1969

Go To URL
Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer.
 

Author(s): Shigeo Koido, Masato Okamoto, Masanori Kobayashi, Shigetaka Shimodaira, Haruo Sugiyama

Journal: Discov Med. 2017 08;24(130):41-49.

 

Pancreatic ductal adenocarcinoma (PDA) is characterized by a very poor prognosis, despite novel chemotherapeutic treatments. Moreover, the majority of PDA patients with complete surgical resection show recurrence within 5 years of resection. Therefore, new targeted cancer vaccines ...

Last Updated: 31 Dec 1969

Go To URL
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
 

Author(s): Sheng Zhong, Shuai Qie, Liu Yang, Qi Yan, Linna Ge, Zhongfeng Wang

Journal: Medicine (Baltimore). 2017 Jul;96(30):e7611.

 

Pancreatic cancer (PC) is one of the most lethal digestive system tumors. Most new cases are diagnosed based on metastasis or local aggression and are known as "advanced PC." Recently, studies investigating S-1 have indicated that it has a better clinical curative effect on PC. We ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 14 Dec 2017

Go to URL
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
 

Status: Recruiting

Condition Summary: Advanced Pancreatic Cancer

 

Last Updated: 18 Feb 2018

Go to URL